Suppr超能文献

基于 microRNA 的肾癌分类诊断检测方法的建立与验证。

Development and validation of a microRNA-based diagnostic assay for classification of renal cell carcinomas.

机构信息

Rosetta Genomics Ltd., Rehovot, Israel.

出版信息

Mol Oncol. 2013 Jun;7(3):732-8. doi: 10.1016/j.molonc.2013.03.002. Epub 2013 Mar 26.

Abstract

Renal cancers account for more than 3% of adult malignancies and cause more than 13,000 deaths per year in the US alone. The four most common types of kidney tumors include the malignant renal cell carcinomas; clear cell, papillary, chromophobe and the benign oncocytoma. These histological subtypes vary in their clinical course and prognosis, and different clinical strategies have been developed for their management. In some kidney tumor cases it can be very difficult for the pathologist to distinguish between tumor types on the basis of morphology and immunohistochemistry (IHC). In this publication we present the development and validation of a microRNA-based assay for classifying primary kidney tumors. The assay, which classifies the four main kidney tumor types, was developed based on the expression of a set of 24 microRNAs. A validation set of 201 independent samples was classified using the assay and analyzed blindly. The assay produced results for 92% of the samples with an accuracy of 95%.

摘要

肾细胞癌占成人恶性肿瘤的 3%以上,仅在美国每年就导致超过 13000 人死亡。四种最常见的肾肿瘤类型包括恶性肾细胞癌、透明细胞癌、乳头状癌、嫌色细胞癌和良性嗜酸细胞瘤。这些组织学亚型在临床过程和预后上有所不同,因此针对它们的管理制定了不同的临床策略。在某些肾肿瘤病例中,病理学家仅基于形态学和免疫组织化学(IHC)很难区分肿瘤类型。在本出版物中,我们介绍了一种基于 microRNA 的检测方法的开发和验证,用于对原发性肾肿瘤进行分类。该检测方法基于一组 24 个 microRNAs 的表达,可对四种主要的肾肿瘤类型进行分类。使用该检测方法对 201 个独立样本的验证集进行分类,并进行盲法分析。该检测方法对 92%的样本进行了分类,准确率为 95%。

相似文献

4
MicroRNAs in Renal Cell Carcinoma.肾细胞癌中的微小RNA
Microrna. 2015;4(1):26-35. doi: 10.2174/2211536604666150713105247.
8
[Possibilities of molecular diagnosis of renal cell carcinoma].[肾细胞癌分子诊断的可能性]
Aktuelle Urol. 2014 Sep;45(5):370-3. doi: 10.1055/s-0034-1389946. Epub 2014 Sep 17.

引用本文的文献

4
The Role of MicroRNAs in Kidney Disease.微小RNA在肾脏疾病中的作用。
Noncoding RNA. 2015 Nov 18;1(3):192-221. doi: 10.3390/ncrna1030192.

本文引用的文献

2
Novel agents in renal carcinoma: a reality check.新型肾癌治疗药物:现实审视。
Ther Adv Med Oncol. 2012 Jul;4(4):183-94. doi: 10.1177/1758834012443725.
10
miR-210: More than a silent player in hypoxia.miR-210:在低氧环境中不止是一个沉默的参与者。
IUBMB Life. 2011 Feb;63(2):94-100. doi: 10.1002/iub.427. Epub 2011 Feb 24.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验